MX2017006997A - Proceso para manipular el nivel de contenido de glicano de una glicoproteina. - Google Patents

Proceso para manipular el nivel de contenido de glicano de una glicoproteina.

Info

Publication number
MX2017006997A
MX2017006997A MX2017006997A MX2017006997A MX2017006997A MX 2017006997 A MX2017006997 A MX 2017006997A MX 2017006997 A MX2017006997 A MX 2017006997A MX 2017006997 A MX2017006997 A MX 2017006997A MX 2017006997 A MX2017006997 A MX 2017006997A
Authority
MX
Mexico
Prior art keywords
manipulating
glycoprotein
level
glycan content
content
Prior art date
Application number
MX2017006997A
Other languages
English (en)
Other versions
MX385409B (es
Inventor
R Leiske Daniel
T Trentalange Michael
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55024253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017006997(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2017006997A publication Critical patent/MX2017006997A/es
Publication of MX385409B publication Critical patent/MX385409B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención actual proporciona un método para manipular el contenido de glicano fucosilado en una proteína recombinante.
MX2017006997A 2014-12-01 2015-12-01 Proceso para manipular el nivel de contenido de glicano de una glicoproteína. MX385409B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462085759P 2014-12-01 2014-12-01
PCT/US2015/063271 WO2016089919A1 (en) 2014-12-01 2015-12-01 Process for manipulating the level of glycan content of a glycoprotein

Publications (2)

Publication Number Publication Date
MX2017006997A true MX2017006997A (es) 2017-10-16
MX385409B MX385409B (es) 2025-03-04

Family

ID=55024253

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006997A MX385409B (es) 2014-12-01 2015-12-01 Proceso para manipular el nivel de contenido de glicano de una glicoproteína.

Country Status (22)

Country Link
US (6) US10167492B2 (es)
EP (2) EP3227454B1 (es)
JP (4) JP6698681B2 (es)
KR (1) KR102623965B1 (es)
CN (1) CN107109455B (es)
AU (5) AU2015355087C1 (es)
CA (1) CA2969225C (es)
CL (1) CL2017001369A1 (es)
CY (1) CY1123247T1 (es)
DK (1) DK3227454T3 (es)
EA (2) EA202091598A3 (es)
ES (1) ES2784503T3 (es)
HU (1) HUE049201T2 (es)
IL (2) IL276165B (es)
LT (1) LT3227454T (es)
MX (1) MX385409B (es)
PL (1) PL3227454T3 (es)
PT (1) PT3227454T (es)
SG (2) SG11201704351WA (es)
SI (1) SI3227454T1 (es)
WO (1) WO2016089919A1 (es)
ZA (2) ZA201703729B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2969225C (en) 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
EP3397282A4 (en) 2015-12-30 2019-08-07 Momenta Pharmaceuticals, Inc. METHODS RELATING TO BIOLOGICA
CA3056011A1 (en) 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
SG11201909087PA (en) * 2017-03-31 2019-10-30 Boehringer Ingelheim Int Perfusion medium
WO2019105444A1 (zh) * 2017-11-30 2019-06-06 正大天晴药业集团南京顺欣制药有限公司 蛋白质的生产方法
US12325737B2 (en) 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
AU2019274782A1 (en) * 2018-05-24 2020-12-03 Ares Trading S.A. Method for controlling the afucosylation level of a glycoprotein composition
EP3802610A1 (en) 2018-06-05 2021-04-14 Amgen Inc. Modulating antibody dependent cellular phagocytosis
US12595454B2 (en) 2018-09-06 2026-04-07 Momenta Pharmaceuticals, Inc. Methods of continuous cell culture
CA3110530A1 (en) 2018-09-11 2020-03-19 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
EA202191352A1 (ru) 2018-11-13 2021-08-11 Янссен Байотек, Инк. Контроль содержания микроэлементов-металлов во время продукции антител к cd38
IL284374B2 (en) * 2018-12-31 2025-10-01 Momenta Pharmaceuticals Inc Methods for producing ozatekinumab
JP2022523063A (ja) * 2019-01-30 2022-04-21 アムジエン・インコーポレーテツド アフリベルセプトの属性、並びにその特性決定及び修飾方法
MX2021013628A (es) 2019-05-06 2022-03-07 Amgen Inc Modulación de las funciones efectoras de anticuerpos.
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
BR112022005583A2 (pt) 2019-09-26 2022-09-20 Amgen Inc Métodos para a produção de composições de anticorpos
WO2021097281A1 (en) 2019-11-15 2021-05-20 Lonza Ltd Process and system for producing an inoculum
US20230287335A1 (en) * 2020-07-30 2023-09-14 Amgen Inc. Cell culture media and methods of making and using the same
KR20230042125A (ko) * 2020-08-14 2023-03-27 브리스톨-마이어스 스큅 컴퍼니 단백질에 대한 제조 공정
KR20230087539A (ko) 2020-10-15 2023-06-16 암젠 인크 항체 생산 방법에서의 상대적인 비결합 글리칸
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
AU2023223660A1 (en) * 2022-02-25 2024-08-01 Kashiv Biosciences, Llc A process for improving polypeptide expression in mammalian cell culture
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
CN121712803A (zh) * 2023-08-16 2026-03-20 葛兰素史密斯克莱知识产权有限公司 控制抗体糖基化谱的方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
DK1666591T3 (da) 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
CN101255192A (zh) 2000-05-26 2008-09-03 布里斯托尔-迈尔斯斯奎布公司 可溶性ctla4突变体分子及其应用
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
DE10312765A1 (de) 2003-03-21 2004-09-30 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Sterilisation flüssiger Medien mittels UV-Bestrahlung und Kurzzeiterhitzung
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070231895A1 (en) 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
EP2495308A1 (en) 2005-12-08 2012-09-05 Amgen Inc. Improved production of glycoproteins using manganese
WO2007081031A1 (ja) * 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides
EP3255141B1 (en) 2006-07-13 2021-12-01 Wyeth LLC Production of antibodies with improved glycosylation pattern
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
ES2541546T3 (es) 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
AU2008223133A1 (en) 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
AU2008232699A1 (en) * 2007-03-30 2008-10-09 Centocor Ortho Biotech Inc. High expression clones of mammalian cells with fluorescent protein A or G
JP2010524467A (ja) 2007-04-16 2010-07-22 モメンタ ファーマシューティカルズ インコーポレイテッド 規定の糖タンパク質産物および関連の方法
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
PL2173861T5 (pl) 2007-06-15 2017-10-31 Amgen Inc Sposoby obróbki nośnika kultury komórkowej do zastosowania w bioreaktorze
CA2763164A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
CN103347537A (zh) * 2010-10-20 2013-10-09 莫弗泰克股份有限公司 抗叶酸受体α抗体糖型
EA201370187A1 (ru) 2011-02-23 2013-12-30 Амген Инк. Клеточная культуральная среда для уфс воздействия и относящиеся к ней способы
CA2829110C (en) * 2011-03-06 2019-01-15 Merck Serono S.A. Low fucose cell lines and uses thereof
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
PT2837680T (pt) 2011-07-01 2020-04-17 Amgen Inc Cultura celular de mamífero
AR087433A1 (es) * 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
TWI583788B (zh) 2011-09-16 2017-05-21 安美基公司 細胞培養之預程式化無回饋控制之連續進料
EA201992617A1 (ru) 2011-10-26 2020-03-10 Амген Инк. Способы уменьшения или устранения модификации и разложения белка, обусловленных воздействием уф-излучения
EP2804946A4 (en) * 2012-01-20 2016-05-25 Agency Science Tech & Res RECOMBINANT CHO GMT PROTEIN EXPRESSION
WO2013114164A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
EP2809773B1 (en) 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
WO2013138159A1 (en) 2012-03-15 2013-09-19 Amgen Inc. Methods of determining exposure to uv light
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
US9714291B2 (en) * 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
SG11201600067YA (en) 2013-07-23 2016-02-26 Biocon Ltd Methods for controlling fucosylation levels in proteins
BR112016017660B1 (pt) * 2014-02-27 2022-04-19 F. Hoffmann-La Roche Ag Método para a produção de uma glicoproteína recombinante
WO2016068799A1 (en) * 2014-10-27 2016-05-06 Agency For Science, Technology And Research Methods of recombinant protein expression in a cell comprising reduced udp-galactose transporter activity
CA2969225C (en) 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein

Also Published As

Publication number Publication date
US20170362625A1 (en) 2017-12-21
US20210017565A1 (en) 2021-01-21
HUE049201T2 (hu) 2020-09-28
AU2015355087B2 (en) 2020-04-09
ES2784503T3 (es) 2020-09-28
KR102623965B1 (ko) 2024-01-11
PL3227454T3 (pl) 2020-07-27
EP3680344A1 (en) 2020-07-15
MX385409B (es) 2025-03-04
JP2022101669A (ja) 2022-07-06
IL276165B (en) 2022-11-01
KR20170083636A (ko) 2017-07-18
US10167492B2 (en) 2019-01-01
BR112017011652A2 (pt) 2018-06-26
AU2024204313A1 (en) 2024-07-11
CL2017001369A1 (es) 2018-02-23
JP2020124216A (ja) 2020-08-20
AU2025223948A1 (en) 2025-09-18
JP2024095777A (ja) 2024-07-10
SI3227454T1 (sl) 2020-06-30
AU2015355087C1 (en) 2025-10-30
SG11201704351WA (en) 2017-06-29
LT3227454T (lt) 2020-07-27
AU2020202302A1 (en) 2020-04-23
IL252569A0 (en) 2017-07-31
EA201791223A1 (ru) 2017-10-31
PT3227454T (pt) 2020-04-06
US20200172947A1 (en) 2020-06-04
EA036178B1 (ru) 2020-10-09
EA202091598A2 (ru) 2020-10-30
CA2969225A1 (en) 2016-06-09
EA202091598A3 (ru) 2021-01-29
JP6698681B2 (ja) 2020-05-27
CN107109455B (zh) 2022-02-18
US20260110013A1 (en) 2026-04-23
IL252569B (en) 2020-08-31
JP7066775B2 (ja) 2022-05-13
DK3227454T3 (da) 2020-04-14
JP2017538446A (ja) 2017-12-28
EP3227454A1 (en) 2017-10-11
EP3227454B1 (en) 2020-01-29
ZA201703729B (en) 2021-03-31
SG10202002458PA (en) 2020-04-29
AU2022200586A1 (en) 2022-02-24
CA2969225C (en) 2023-08-22
CY1123247T1 (el) 2021-10-29
WO2016089919A1 (en) 2016-06-09
US20230159974A1 (en) 2023-05-25
CN107109455A (zh) 2017-08-29
ZA202006002B (en) 2022-03-30
US10822630B2 (en) 2020-11-03
AU2015355087A1 (en) 2017-06-29
US20190085370A1 (en) 2019-03-21
IL276165A (en) 2020-09-30

Similar Documents

Publication Publication Date Title
MX2017006997A (es) Proceso para manipular el nivel de contenido de glicano de una glicoproteina.
IL283280B1 (en) Providing bacteria-based proteins
EP3217807A4 (en) Methods and compositions for egg white protein production
EP3172443A4 (en) System and method for reinforcing reciprocating pump
SG11201609677WA (en) Method for reducing the chlorine content of organomonophosphites using dimethylaminobutane, triethylamine or triethanolamine
EP3312278A4 (en) Protein expression method
EP3131925A4 (en) Modified relaxin b chain peptides
EP3133932A4 (en) Egg white processing
EP3156484A4 (en) Method for judging protein interaction
EP3135763A4 (en) Method for improving protein expression, and composition for protein expression
GB201703416D0 (en) Method for protein expression
FI20146005A7 (fi) Menetelmä massan valmistamiseksi.
GB2556396B (en) Method for Hydrolysing protein materials
TH1601003638A (th) วัสดุที่ใช้สูบแบบมีวาล์ว
GB201603763D0 (en) Method for protein expression
ITUA20162407A1 (it) Metodo per la riqualificazione di condotte in pressione.
TH1601000293A (th) วิธีสำหรับควบคุมระดับฟิวโคสิเลชันในโปรตีน
EP3221449A4 (en) Process for refolding recombinant chymotrypsin
FI20146113A7 (fi) Proteiinien konsentrointimenetelmä
TH1701002005B (th) วัสดุเหล็กกล้าที่รีดแล้วสำหรับก้านต่อชนิดการแยกออกด้วยการแตกหัก
TH1501004638A (th) วิธีการสำหรับการขับเร้าวาล์วแบบกึ่งปฏิบัติการตามคำสั่ง และระบบสำหรับการขับเร้า วาล์วแบบกึ่งปฏิบัติการตามคำสั่งสำหรับคอมเพรสเซอร์แบบเคลื่อนสลับไปมาชนิดดูดหลายทาง
PH32014000246S1 (en) Reciprocating saw
TH1601005519B (th) ถังพักสำหรับคอมเพรสเซอร์
GB201515337D0 (en) Protein Expression
AU2014901409A0 (en) Modified relaxin B chain peptides